coteau ARQ.

BLSM

BlossomHill Therapeutics, Inc.
$14.63
−$1.18 (7.46%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-19%+4%+28%+51%+75%Aug 7Oct 23Sep 1452w high $27.9952w low $12.93
BLSMSPY
Wall St. Highest PT $40.00 (+173.4%) Wall St. Avg PT $35.40 (+142.0%)
$14$24$34$45$55POC $16Hi $40Avg $35
Underwater Drawdown %Max DD -48.0%Current -45.5%
0.0%-48.0%
Relative Strength vs SPY-7.1% vs SPYUnderperforming
+79%0%-79%
1W
+$0.69 (4.95%)
1M
−$7.71 (34.51%)
3M
–
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
5 analysts · mean score 1.20
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$14.63
Average target$35.40
+$20.77 (+142.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$30.00
Median$35.40
High$40.00
12-month Wall Street target range
Recent analyst rating changes · 7
Reiterated
2026-09-21 · Leerink Partners reiterated Outperform on BLSM
Reiterated
2026-09-21 · Guggenheim reiterated Buy on BLSM
Initiated
2026-09-01 · LifeSci Capital started covering BLSM at Outperform
Initiated
2026-09-01 · Leerink Partners started covering BLSM at Outperform
Initiated
2026-09-01 · JP Morgan started covering BLSM at Overweight
Initiated
2026-09-01 · Guggenheim started covering BLSM at Buy
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$465.0M
P/E (next 12 months, estimated)-3.7
52-week range$12.93 – $27.99
Dividend yieldNo dividend
Analyst consensusStrong Buy (5)
Average analyst price target$35.40 (+142%)

What they do

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for BLSM yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

BLSM earningsNext report in 22 days
Next report
Mon Nov 16, 2026Before the open
EPS consensus-$0.90 range -$0.92–-$0.88
Revenue consensus$0 5 analysts
Source: Yahoo Finance · refreshed 2026-10-24 02:38:15 ET
No EPS history available.

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-06-30$0–
2025-03-31$0–

News & catalysts

More news
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
GlobeNewswire · Oct 22
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
GlobeNewswire · Sep 28
BlossomHill Therapeutics Q2 Loss Widens
MT Newswires · Sep 18
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
GlobeNewswire · Sep 18
BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update
InvestorsHub · Sep 15
Rating changes
Reiterated
2026-09-21 · Leerink Partners reiterated Outperform on BLSM
Reiterated
2026-09-21 · Guggenheim reiterated Buy on BLSM
Initiated
2026-09-01 · LifeSci Capital started covering BLSM at Outperform
Initiated
2026-09-01 · Leerink Partners started covering BLSM at Outperform
Initiated
2026-09-01 · JP Morgan started covering BLSM at Overweight
Initiated
2026-09-01 · Guggenheim started covering BLSM at Buy

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 02:38:15 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026